Paul D'Amico, PhD, RN, NP

Paul D'Amico, PhD, RN, NP

Smithtown, New York, United States
2K followers 500+ connections

Join to follow

About

PhD prepared Nurse Practitioner (NP) with over 40 years in the healthcare industry and 30…

Activity

Join now to see all activity

Experience

  • Pfizer Graphic

    Pfizer

    New York, New York, United States

  • -

    Stony Brook, NY

  • -

  • -

    New York, United States

  • -

    New York, New York

  • -

    New York, New York

  • -

    Greater New York City Area

  • -

    Greater New York City Area

  • -

    Greater New York City Area

  • -

  • -

  • -

  • -

  • -

  • -

  • -

  • -

  • -

    Manhasset, NY

  • -

  • -

  • -

  • -

  • -

  • -

Education

  • Duquesne University Graphic

    Duquesne University

    -

    Dissertation: Oncology nurses’ attitudes toward cancer clinical trials and their perceptions to patients’ understanding

  • -

    Three-course certificate program, examines how to apply the principles of health economics to improve decision-making in a complex health care environment. Investigate health care markets and systems throughout the world and evaluate the effectiveness of medical treatments, interventions and technologies through outcomes research. Develop the ability to use economic assessments to improve health care decisions involving patients, providers, businesses and government agencies.

  • -

    The certificate program consists of three sequential 3.0 credit courses. The curriculum reflects core epidemiological and biostatistical concepts and practices. It provides research-oriented training in the theory and tools of core public health disciplines. Students build the statistical background needed to conduct research, develop hypotheses, analyze data, and interpret and communicate results.

  • -

  • -

Volunteer Experience

  • Research Review Committee

    International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

    - Present 8 years

    Health

    IISPOR: Member of Research Review Committee
    • Clinical Outcomes Studies
    • Patient-Reported Outcomes & Patient Preference Studies

  • Founding Board Member

    LifeSci Industry Nurses Association (LINA)

    - Present 10 months

Publications

  • Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)

    Journal of Cancer Investigation and Clinical Oncology

    Acute myeloid leukemia (AML) is a life-threatening malignancy that is more prevalent in the elderly. Because the patient population is heterogenous and advanced in age, choosing the optimal therapy can be challenging. There is strong evidence supporting antileukemic therapy, including standard intensive induction chemotherapy (IC) and non-intensive chemotherapy (NIC), for older patients with AML, and guidelines recommend treatment selection based on a patient’s individual and disease…

    Acute myeloid leukemia (AML) is a life-threatening malignancy that is more prevalent in the elderly. Because the patient population is heterogenous and advanced in age, choosing the optimal therapy can be challenging. There is strong evidence supporting antileukemic therapy, including standard intensive induction chemotherapy (IC) and non-intensive chemotherapy (NIC), for older patients with AML, and guidelines recommend treatment selection based on a patient’s individual and disease characteristics as opposed to age alone. Nonetheless, historic evidence indicates that a high proportion of patients who may be candidates for NIC receive no active antileukemic treatment (NAAT), instead receiving only best supportive care (BSC). We conducted a focused literature review to assess current real-world patterns of undertreatment in AML. From a total of 25 identified studies reporting the proportion of patients with AML receiving NAAT, the proportion of patients treated with NAAT varied widely, ranging from 10 to 61.4% in the US and 24.1 to 35% in Europe.

    Characteristics associated with receipt of NAAT included clinical factors such as age, poor performance status, comorbidities, and uncontrolled concomitant conditions, as well as sociodemographic factors such as female sex, unmarried status, and lower income. Survival was diminished among patients receiving NAAT, with reported median overall survival values ranging from 1.2 to 4.8 months compared to 5 to 14.4 months with NIC. These findings suggest a proportion of patients who are candidates for NIC receive NAAT, potentially forfeiting the survival benefit of active antileukemic treatment.

    Other authors
    See publication

  • Gemtuzumab ozogamicin plus standard chemotherapy carries a comparable burden of hospitalization compared with standard chemotherapy alone in acute myeloid leukemia

    Value in Health

    This post hoc analysis included participants aged 50-70 years with treatment-naïve AML from the ALFA-0701 trial (NCT00927498), who received fractionated dose GO + SC (n=131) or SC alone (n=137). All patients were hospitalized for treatment administration. We compared number of admissions (planned or unplanned) and LOS with GO + SC vs SC, in the as-treated population and by treatment phase (induction vs consolidation). Data shown are for the safety reporting period (up to 28 days after last dose…

    This post hoc analysis included participants aged 50-70 years with treatment-naïve AML from the ALFA-0701 trial (NCT00927498), who received fractionated dose GO + SC (n=131) or SC alone (n=137). All patients were hospitalized for treatment administration. We compared number of admissions (planned or unplanned) and LOS with GO + SC vs SC, in the as-treated population and by treatment phase (induction vs consolidation). Data shown are for the safety reporting period (up to 28 days after last dose of study treatment).

    This analysis shows that, in the ALFA-0701 trial, adding GO to SC for frontline AML did not significantly alter the associated hospitalization burden. Adding GO to SC is therefore not expected to increase healthcare resource utilization or related costs.

    Other authors
    See publication

  • Implementation of problem solving therapy to depressed home-bound seniors.

    The Gerontologist, Volume 56, Issue Suppl_3, 1 November 2016, Pages 59

    Other authors
    See publication

  • Oncology nurses’ attitudes toward cancer clinical trials and their perceptions to patients’ understanding.

    ProQuest Information and Learning Company.

    Doctoral dissertation.

  • The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study

    Cancer Investigation, Vol. 20, Nos. 7&8, pp. 904-913.

    Other authors
    • Lichtman, S.L.
    • Etcubanas, E
    • Budman, D.R
    • Eisenberg, P
    • Zervos, G
    • O'Mara, V
    • Musgrave, K
    • Cascella, P
    • Melikian, A

  • Development of a fludarabine phosphate (FAMP) dosing formulation in patients with renal insufficiency based on a pharmacokinetic (PK) study in patients with and without renal impairment.

    1998 Proc. ASCO, 17, abstract# 845

    Other authors
    • Williams, G
    • Lichtman, S.M
    • Budman, D.R
    • Etcubanas, E
    • Eisenberg, P
    • O’Mara, V
    • Musgrave, K
    • Cascella, P

  • Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT

    Journal of Clinical Oncology

    See publication

Honors & Awards

  • 2024 DNP Faculty Award

    Stony Brook University School of Nursing

    Outstanding Faculty and Service Award from the DNP Class of 2024

  • Faculty

    -

    Faculty for the 2016 Health Economics and Outcomes Research Writing Workshop, HEOR Study Designs Explained.

  • Faculty

    -

    Faculty for the Health Economics and Outcomes Research Writing Webinar Series, HEOR Study Designs Explained: Blending Messages with Methods

  • Roche Global Outstanding Perjeta Neoadjuvant Launch in the U.S. Award

    -

  • Field USMA ACE Partnership/Collaborator Award

    -

Organizations

  • International Society of Pharmacoeconomic and Outcomes Research (ISPOR)

    -

    - Present

  • American Association for Cancer Research (AACR)

    -

    - Present

  • American Society of Clinical Oncology (ASCO)

    -

    - Present

More activity by Paul

View Paul’s full profile

  • See who you know in common
  • Get introduced
  • Contact Paul directly
Join to view full profile

Other similar profiles

Explore more posts

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses